Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
about
Fc glycans of therapeutic antibodies as critical quality attributesIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activityIgG1 Fc N-glycan galactosylation as a biomarker for immune activationDimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methodsTime-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsBiosimilarity Versus Manufacturing Change: Two Distinct Concepts.Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation.A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.General solutions to decompose heterogeneous compositions using antibody afucosylation as a model system.Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.Challenges with afucosylation content in antibody-based drugs: Guidance provided by mathematical modeling.A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins.Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013.Process parameters impacting product quality.Separation of nonfucosylated antibodies with immobilized FcγRIII receptors.N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.Modulation of mAb quality attributes using microliter scale fed-batch cultures.Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review.
P2860
Q26799266-8DF902AD-1260-4757-AC6B-569549BDD65BQ28547176-E79503F3-6ECC-402C-BB99-96982F47AC88Q28601166-E6430CA0-C7EF-42D4-A3B6-0FFCBABE6D62Q30390233-67497838-3BF1-4D62-8E20-089A7670A2F8Q36213066-06D71655-D7B6-4930-B0CA-BC1C251D1D10Q36213158-D4233729-B594-4293-9959-F405B013A45EQ36216323-D11B0359-4743-4874-BFDD-438135910B94Q36239584-EB15E97F-D8DB-4FB3-983E-68B8AAB36DBBQ37496563-C85F749A-1816-4DC4-80E1-DF978DEDB08EQ37589825-851A7CA3-E387-4EB4-9D61-5932F70FFB0CQ38588544-3F3E3551-A18D-4D6B-839B-03947CA6DDEFQ38628086-A6BB36F2-1F0A-4AED-8A8B-44D199566E4BQ38699354-2526766A-880D-4A62-9D97-FD0D4A8FB3BCQ38849069-C6761FC0-FEE2-4849-8266-A5080732FF82Q38849956-F8317ED9-E2B4-489B-BAB5-2219AC31232AQ39004366-C9C87771-87E7-43D2-9DE9-1A52A3E4C405Q39064312-4CFDC24E-3768-4DD5-990F-C96EF9A4353BQ39155369-1473E9D6-6363-4E24-83BC-3C12B8400A40Q39782184-03AC8A8C-798D-4497-A4BC-C8F5299E87F4Q41491243-D913D991-1337-47E9-88CC-FCFE74ED8BD3Q42280824-7EA61251-70DA-4D65-9DFD-4A2BD71A00AAQ42390676-BFD33F62-1E77-4F2E-AA82-ECDA6080C38CQ42792700-61A3B6CE-4C4F-4D31-AB0C-187F6F3C2180Q46251188-682C4736-5540-4DAE-9FEF-983E56BE46A6Q46360891-BF8EA951-E25B-4DF1-9407-D7537AF5B5D9Q47311471-20DB4721-D5C2-4196-9F28-2414654612CFQ48278134-2F7FAF52-3217-4671-AE33-939D2A9D352EQ49979586-23F70AE0-A80C-493E-98EE-9F361A117B87Q50199955-335138E4-C84E-45B7-A03D-5829A9B224BEQ51749017-7FF3A2DC-4E48-4D71-8862-F19F35682DA5Q55333943-5AF29914-7857-4288-97B9-C4F16F29CEAB
P2860
Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@en
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@nl
type
label
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@en
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@nl
prefLabel
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@en
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@nl
P2093
P2860
P356
P1476
Quantitative evaluation of fuc ...... iated cytotoxicity activities.
@en
P2093
Chris Fong
Martin Vanderlaan
Shan Chung
Valerie Quarmby
Xiaoying Gao
P2860
P304
P356
10.4161/MABS.19941
P577
2012-04-26T00:00:00Z